Price T Rowe Associates Inc Gemini Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $4.74 Million - $10.5 Million	-750,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $8.49 Million - $13.5 Million	750,000 New	750,000 $9.65 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.